Skip to main content
. 2012 May 25;7(5):e37628. doi: 10.1371/journal.pone.0037628

Figure 1. Schematic illustration of ADAM12 indicating the published breast cancer-associated mutations and the di-leucine motif in the cytoplasmic tail.

Figure 1

Schematic illustration of the domain organization of ADAM12. S: Signal peptide; Pro: Prodomain; Met: Metalloprotease domain; Dis: Disintegrin domain; Cys: Cysteine-rich domain; EGF: EGF-like domain; TM: Transmembrane domain; Cyt: Cytoplasmic tail. Positions of the three breast cancer-associated mutations are indicated and the amino acid sequence containing the di-leucine motif is shown.